AARD SCHEDULE 13G/A: SEC filing

Citadel Advisors LLC and affiliated entities

Filed with the SEC on · accession 0001104659-26-128212

AARD filed a SCHEDULE 13G/A (schedule 13g/a) with the SEC on Nov 16, 2026. Citadel Advisors LLC and affiliated entities filed an amended Schedule 13G reporting beneficial ownership of approximately 4.3% of Aardvark Therapeutics' common stock, with Kenneth Griffin deemed to beneficially own 4.5%. The stock moved -5.3% by the first close after the filing.

Summary of the filing

Citadel Advisors LLC and affiliated entities filed an amended Schedule 13G reporting beneficial ownership of approximately 4.3% of Aardvark Therapeutics' common stock, with Kenneth Griffin deemed to beneficially own 4.5%. The filing is a passive investment disclosure with no intent to influence control.

Key details

Shares beneficially owned by Citadel Advisors LLC et al.$942K
Shares beneficially owned by Citadel Securities LLC$11K
Shares beneficially owned by Citadel Securities Group LP et al.$44K
Shares deemed beneficially owned by Kenneth Griffin$986K
Reporting person; beneficial owner of 941,677 shares (4.3%)Citadel Advisors LLC
Reporting person; may be deemed beneficial owner of 941,677 shares (4.3%)Citadel Advisors Holdings LP
Reporting person; may be deemed beneficial owner of 941,677 shares (4.3%)Citadel GP LLC
Reporting person; beneficial owner of 11,049 shares (0.1%)Citadel Securities LLC
Reporting person; may be deemed beneficial owner of 44,400 shares (0.2%)Citadel Securities Group LP
Reporting person; may be deemed beneficial owner of 44,400 shares (0.2%)Citadel Securities GP LLC
IssuerAardvark Therapeutics, Inc.
President and ceo of citadel gp llcKenneth Griffin
Authorized signatorySeth Levy

How AARD stock reacted

Close before

$1.33

Nov 13, 2026

First close after

-5.26%

$1.26

5 trading days

—

Since filing

—

✦ Ask GOAX AI about this filing — what it means for AARD, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for AARD?

Click here

Frequently asked questions

What did AARD file with the SEC on Nov 16, 2026?

AARD filed a SCHEDULE 13G/A (SEC filing). Citadel Advisors LLC and affiliated entities filed an amended Schedule 13G reporting beneficial ownership of approximately 4.3% of Aardvark Therapeutics' common stock, with Kenneth Griffin deemed to beneficially own 4.5%. The filing is a passive investment disclosure with no intent to influence control.

How do I read a SCHEDULE 13G/A?

A report the company filed with the SEC (the US market regulator). Start with the summary, then the key amounts and names. Compare it with the company’s earlier filings.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A SCHEDULE 13G/A (schedule 13g/a): A report the company filed with the SEC (the US market regulator).

How did AARD stock react to this filing?

AARD closed at $1.33 before the filing and $1.26 on Nov 16, 2026 (-5.26%).

Other AARD SEC filings

Get alerts when AARD files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days